CardioLabs, Inc.

CardioLabs, Inc. specializes in advanced cardiovascular diagnostics, providing innovative tools that enhance patient outcomes through effective disease detection and management. Founded in 1995 in Franklin, US, CardioLabs, Inc. focuses on developing cardiovascular diagnostic solutions.

In June 2021, the company was acquired by AliveCor, Inc. , which aimed to enhance its cardiological services. Specific details regarding the founder's history or prior ventures are not available. The company has been involved in a single deal as part of its investment strategy.

CardioLabs specializes in the development and provision of advanced cardiovascular diagnostic tools and services aimed at enhancing patient outcomes. Their suite of products includes state-of-the-art blood analysis systems and software solutions that facilitate the early detection and management of cardiovascular diseases. These technologies enable healthcare providers to analyze key biomarkers and generate comprehensive reports, thus supporting clinical decision-making. CardioLabs targets a diverse clientele, including hospitals, outpatient clinics, and cardiology practices across North America and Europe.

CardioLabs generates revenue primarily through direct sales of its diagnostic products and software services to healthcare institutions. The business operates on a B2B model, engaging in partnerships with hospitals and clinics that utilize its technologies in routine diagnostic processes. Revenue streams include one-time purchases and ongoing service agreements for software updates and maintenance, with flagship blood analysis systems contributing significantly to their sales portfolio. The acquisition of CardioLabs, Inc.

by AliveCor, Inc. in June 2021 is intended to enhance its cardiological offerings to patients requiring monitoring devices prescribed by healthcare providers. Future product launches and market expansion plans have not been disclosed; however, the integration into AliveCor's framework suggests a focus on increasing accessibility and utilization of advanced cardiovascular diagnostics across broader markets.